ArticleScience advances2024
Discovery of SARS-CoV-2 papain-like protease (PL
Abstract read
In one paragraph
Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Hitting Coronaviruses Where It Hurts: Antiviral Strategies Targeting Viral Proteins.ChemMedChem · 2026Review
- Substrate-Selective Inhibition of the SARS-CoV-2 Papain-Like Protease: Inhibition of Hydrolysis of Human Over Viral Substrates.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Nitrile-Based Inhibitors Targeting both SARS-CoV‑2 Main Protease and Human Cathepsin L.ACS medicinal chemistry letters · 2026Article
- Recent Advances in the Design of Inhibitors Targeting the Viral Entry and Replication of the SARS-CoV-2 Virus, Driven by In Silico Approaches.Molecules (Basel, Switzerland) · 2026Review
- Discovery of novel druggable binding pockets on SARS-CoV-2 PLpro via fragment screening and insights for structure-based inhibitor design.The Journal of biological chemistry · 2026Article
- SARS-CoV-2 3CLpro inhibits the replication of influenza viruses through the cleavage of NP and PA.Virologica Sinica · 2026Article
- Understanding protein ISGylation, a multifaceted posttranslational modification.Cell chemical biology · 2026Review
- Structure-Guided Discovery of Selective Polo-Like Kinase 3 Inhibitors.ACS medicinal chemistry letters · 2026Article
- Targeting SARS-CoV-2 Non-Structural Proteins: A Blueprint for Next-Generation Small-Molecule Coronavirus Antivirals.Pharmaceutics · 2026Review
- Inhibitors Targeting SARS-CoV-2 Papain-Like Protease: Screening, Design, Synthesis, and Biological Evaluation.ChemMedChem · 2026Article
- Extending the Targets for Coronavirus Antivirals Beyond That of Approved Drugs: Insights From Preclinical Research.Microbial biotechnology · 2026Review
- Enhanced Antiviral Activity of Novel Umifenovir Derivatives against SARS-CoV-2: Insights from an International Collaborative Study.ACS omega · 2026Article
- Discovery of the SARS-CoV-2 Papain-Like Protease Inhibitor MR1-114: From Structure-Based Design toJournal of medicinal chemistry · 2026Article
- Discovery of Spiro[chromane-2,4'-piperidine] Derivatives as Irreversible Inhibitors of SARS-CoV-2 Papain-like Protease.Journal of medicinal chemistry · 2026Article
- Structural Basis and Inhibitor Development of SARS-CoV-2 Papain-like Protease.Molecules (Basel, Switzerland) · 2026Review
- YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice.Nature communications · 2026Article
- Discovery of Fragment-Based Inhibitors of SARS-CoV-2 PLJournal of medicinal chemistry · 2026Article
- Stability-Driven Pose Prediction and Ligand Design via Contact Persistence Analysis from Molecular Dynamics Simulations.Computational and structural biotechnology journal · 2026Article
- Discovery of SARS-CoV-2 PLpro inhibitors and RIPK1 inhibitors with synergistic antiviral efficacy in a mouse COVID-19 model.Acta pharmaceutica Sinica. B · 2026Article
- Insights from deep mutational scanning in the context of an emerging pathogen.Biochemical Society transactions · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
40 authors.
Michelle R GarnseyPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0003-1226-1868
Matthew C RobinsonPostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.ORCID 0009-0001-3935-9083
Luong T NguyenPostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.
Rhonda CardinPfizer Global Research and Development, Pearl River, NY 10965, USA.ORCID 0000-0003-2390-8591
Joseph TillotsonPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0003-0795-5494
Ellene MashalidisPfizer Global Research and Development, Groton, CT 06340, USA.
Aijia YuWuXi, WuXi AppTec (Shanghai) Co. Ltd. Shanghai 200131, China.ORCID 0009-0008-6374-2518
Lisa AschenbrennerPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0009-0005-2921-068X
Amanda BalesanoPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0009-0001-7641-1127
Amin BehzadiPfizer Global Research and Development, Pearl River, NY 10965, USA.ORCID 0000-0002-1691-6123
Britton BorasPfizer Global Research and Development, La Jolla, CA 92121, USA.ORCID 0000-0003-3624-9177
Jeanne S ChangPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0000-0002-8043-8621
Heather EngPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0000-0002-2914-3967
Andrew EphronPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0009-0002-9750-2447
Tim FoleyPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0000-0002-5987-5253
Kristen K FordPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0009-0003-2915-8063
James M FrickPostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.ORCID 0009-0003-7536-0086
Scott GibsonInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences,Utah State University, Logan, UT 84322, USA.
Li HaoPfizer Global Research and Development, Pearl River, NY 10965, USA.ORCID 0000-0002-8865-7351
Brett HurstInstitute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences,Utah State University, Logan, UT 84322, USA.ORCID 0000-0003-1025-5878
Amit S KalgutkarPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0001-9701-756X
Magdalena KorczynskaPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0002-1339-5553
Zsofia Lengyel-ZhandPfizer Global Research and Development, Groton, CT 06340, USA.
Liping GaoWuXi, WuXi AppTec (Shanghai) Co. Ltd. Shanghai 200131, China.
Hannah R MeredithPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0002-5315-7568
Nandini C PatelPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0002-2735-7662
Jana PolivkovaPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0009-0002-4011-9447
Devendra RaiPfizer Global Research and Development, Groton, CT 06340, USA.
Colin R RosePfizer Global Research and Development, Groton, CT 06340, USA.
Hussin RothanPfizer Global Research and Development, Pearl River, NY 10965, USA.
Sylvie K SakataPfizer Global Research and Development, La Jolla, CA 92121, USA.ORCID 0009-0003-2314-3979
Thomas R VargoPostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.ORCID 0009-0003-4203-5754
Wenying QiWuXi, WuXi AppTec (Shanghai) Co. Ltd. Shanghai 200131, China.ORCID 0009-0002-4328-7008
Huixian WuPfizer Global Research and Development, Groton, CT 06340, USA.ORCID 0000-0003-1357-9747
Yiping LiuWuXi, WuXi AppTec (Shanghai) Co. Ltd. Shanghai 200131, China.
Irina YurgelonisPfizer Global Research and Development, Pearl River, NY 10965, USA.ORCID 0009-0003-2081-7907
Jinzhi ZhangPfizer Global Research and Development, Shanghai 201210, China.ORCID 0009-0009-7198-2535
Yuao ZhuPfizer Global Research and Development, Pearl River, NY 10965, USA.ORCID 0000-0001-9831-6836
Lei ZhangPfizer Global Research and Development, Cambridge, MA 02139, USA.ORCID 0000-0001-8118-1402
Alpha A LeePostEra, 1 Broadway, 14th floor, Cambridge, MA 02142, USA.ORCID 0000-0002-9616-3108
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines and first-generation antiviral therapeutics have provided important protection against COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, there remains a need for additional therapeutic options that provide enhanced efficacy and protection against potential viral resistance. The SARS-CoV-2 papain-like protease (PL
Indexed as
Antiviral AgentsCoronavirus Papain-Like ProteasesCOVID-19 Drug TreatmentDisease Models, AnimalSARS-CoV-2AnimalsCoronavirus 3C ProteasesCOVID-19FemaleHumansMachine LearningMiceProtease InhibitorsVirus ReplicationAntiviral AgentsCoronavirus 3C ProteasesCoronavirus Papain-Like Proteasespapain-like protease, SARS-CoV-2Protease Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.